SASE:4004

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

ر.س7.0b

Last Updated

2021/06/17 14:33 UTC

Data Sources

Company Financials +

Executive Summary

Dallah Healthcare Company provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. More Details


Snowflake Analysis

Moderate growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has Dallah Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4004 is not significantly more volatile than the rest of SA stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4004's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

4.7%

4004

-0.05%

SA Healthcare

-0.07%

SA Market


1 Year Return

103.3%

4004

105.6%

SA Healthcare

15.5%

SA Market

Return vs Industry: 4004 underperformed the SA Healthcare industry which returned 105.6% over the past year.

Return vs Market: 4004 exceeded the SA Market which returned 15.5% over the past year.


Shareholder returns

4004IndustryMarket
7 Day4.7%-0.05%-0.07%
30 Day17.8%8.8%0.7%
90 Day46.1%35.2%4.1%
1 Year106.4%103.3%109.7%105.6%19.9%15.5%
3 Year36.7%27.8%48.0%40.7%41.8%28.3%
5 Year55.5%38.8%54.3%41.2%94.7%64.9%

Long-Term Price Volatility Vs. Market

How volatile is Dallah Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dallah Healthcare undervalued compared to its fair value and its price relative to the market?

52.12x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 4004 (SAR78) is trading above our estimate of fair value (SAR28.12)

Significantly Below Fair Value: 4004 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4004 is poor value based on its PE Ratio (52.1x) compared to the SA Healthcare industry average (41.1x).

PE vs Market: 4004 is poor value based on its PE Ratio (52.1x) compared to the SA market (32.1x).


Price to Earnings Growth Ratio

PEG Ratio: 4004 is poor value based on its PEG Ratio (5.3x)


Price to Book Ratio

PB vs Industry: 4004 is overvalued based on its PB Ratio (3.9x) compared to the SA Healthcare industry average (2.7x).


Future Growth

How is Dallah Healthcare forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

9.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4004's forecast earnings growth (9.8% per year) is above the savings rate (8.8%).

Earnings vs Market: 4004's earnings (9.8% per year) are forecast to grow faster than the SA market (8.2% per year).

High Growth Earnings: 4004's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4004's revenue (7.6% per year) is forecast to grow faster than the SA market (3.9% per year).

High Growth Revenue: 4004's revenue (7.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4004's Return on Equity is forecast to be low in 3 years time (13.2%).


Past Performance

How has Dallah Healthcare performed over the past 5 years?

-15.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4004 has high quality earnings.

Growing Profit Margin: 4004's current net profit margins (8.7%) are lower than last year (10.5%).


Past Earnings Growth Analysis

Earnings Trend: 4004's earnings have declined by 15.9% per year over the past 5 years.

Accelerating Growth: 4004's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4004 had negative earnings growth (-0.4%) over the past year, making it difficult to compare to the Healthcare industry average (23.8%).


Return on Equity

High ROE: 4004's Return on Equity (7.2%) is considered low.


Financial Health

How is Dallah Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: 4004's short term assets (SAR1.0B) exceed its short term liabilities (SAR753.0M).

Long Term Liabilities: 4004's short term assets (SAR1.0B) do not cover its long term liabilities (SAR1.4B).


Debt to Equity History and Analysis

Debt Level: 4004's debt to equity ratio (78.3%) is considered high.

Reducing Debt: 4004's debt to equity ratio has increased from 28.5% to 78.3% over the past 5 years.

Debt Coverage: 4004's debt is not well covered by operating cash flow (14.6%).

Interest Coverage: 4004's interest payments on its debt are well covered by EBIT (6.6x coverage).


Balance Sheet


Dividend

What is Dallah Healthcare current dividend yield, its reliability and sustainability?

0.96%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4004's dividend (0.96%) isn’t notable compared to the bottom 25% of dividend payers in the SA market (1.51%).

High Dividend: 4004's dividend (0.96%) is low compared to the top 25% of dividend payers in the SA market (4.53%).


Stability and Growth of Payments

Stable Dividend: 4004 is not paying a notable dividend for the SA market, therefore no need to check if payments are stable.

Growing Dividend: 4004 is not paying a notable dividend for the SA market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 4004 is not paying a notable dividend for the SA market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4004's dividend in 3 years as they are not forecast to pay a notable one for the SA market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Ahmad bin Babaeer (62 yo)

0.17

Tenure

ر.س8,000

Compensation

Dr. Ahmad bin Saleh Babaeer serves as the Chief Executive Officer of Dallah Healthcare Company since April 2021. Dr. Babaeer served as General Manager of Dallah Hospital at Dallah Healthcare Holding Co. Dr...


Leadership Team

Experienced Management: 4004's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: 4004's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.


Top Shareholders

Company Information

Dallah Healthcare Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dallah Healthcare Company
  • Ticker: 4004
  • Exchange: SASE
  • Founded: 1994
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: ر.س7.020b
  • Shares outstanding: 90.00m
  • Website: https://www.dallahhealth.com

Location

  • Dallah Healthcare Company
  • King Fahed Road
  • Nakhil
  • Riyadh
  • 12381
  • Saudi Arabia

Listings


Biography

Dallah Healthcare Company provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthc...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 14:33
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.